Pioneering the Precision Oncology Field

We are committed to improve patient care standards and advancing precision oncology through the utilization of NGS technology. We believe that increased molecular testing provides clinicians with the tools to make better-informed decisions about therapy selection. The rationale is simple: every case of cancer is different, and every patient’s genetic profile is unique, and thus individualized therapy should be considered as the gold-standard for treating cancer patients.

Why are We Unique?

NGS Market Leader in China

Burning Rock is the industry leader for NGS precision oncology testing in China with around one-third overall market share and an 80% in-hospital market share.

Value and Accessibility

Our goal is to increase the accessibility of molecular genetic assays to enable more widespread testing at a lower cost as compared to peers.

World Class Assay Performance Validated by FDA Led Assessment

#2 is Sensitivity and LoD in FDA led assessment of 8 leading NGS oncology panels vendors. #1 in ctDNA Panel comparison.

Custom Assays

Burning Rock offers custom assays and fit-for-purpose validation, including novel applications such as RNA Seq, WES, digital pathology, and MRD. Custom assay development from RUO to IVD.

Tissue and Liquid Biopsy

We offer our partners true flexibility of testing and are proficient with both tissue and liquid panels, emphasizing the advantages of both as complementary tests such as a built-in concordance check, which allows for improved differentiation between germline and somatic mutations via buffy coat (WBC) analysis which is important for certain hereditary cancers.

Global Trial Capability

As the only company worldwide with a CLIA/CAP laboratory in both the United States and China, Burning Rock can enable our partners to run global trials. We have global regulatory experience in China, the United States, EU, and Japan.

By the Numbers

Total Test – FFPE and Liquid


Peer-Reviewed Publications


Days Turnaround Time


Biopharma Collaborations


Hospitals in Network


Physicians Assisted


Largest Lung Cancer Database in the World


Industry-Leading Performance

Burning Rock Dx’s NGS Liquid and Tissue panels feature leading assay performance in specificity, sensitivity, and concordance with the industry gold standard.

Our panels’ performances are validated by independent assessment against some of the leading biotechnology companies in the current oncology space.

Read More

Our 94% (FFPE) and >99% (Blood) success rate ensures that the patient’s valuable samples are processed correctly, and yield results the first time around.

BR’s IVD kit capability allows for global deployment of our assays, enabling multi-site and global trials as well as increased concordance amongst distinct laboratories.

We offer outstanding value per test and can fulfill custom projects at a substantially lower price point in comparison to competitors.



Treatment Selection

Clinical Trial Enrollment, Therapy Selection Guidance, Patient Recruitment.


Treatment Monitoring, Drug Efficacy Monitoring, Predictive Evaluation.

Early Detection

Early Detection of at Risk Population, Methylation based ELSA Seq assay.
Read More

Contact Us

We look forward to hearing from you. Whether you are an academic collaborator or a potential biopharma partner, feel free to reach out and our team will get back to you as soon as possible.

Call Us


Send Us A Message